Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ACE-232 in Patients With Metastatic Castration-Resistant Prostate Cancer (CRPC)

NCT06801236 is registered in ClinicalTrials.gov with Acerand Therapeutics (Hong Kong) Limited as lead sponsor.

NCT NCT06801236
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06801236 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ACE-232 in Patients With Metastatic Castration-Resistant Prostate Cancer (CRPC)
Lead sponsor
Acerand Therapeutics (Hong Kong) Limited
Phase
Phase 1
Overall status
Recruiting
Start date
May 12, 2025
Completion date
December 31, 2028
Enrollment
88 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

mcrpc (metastatic castration-resistant prostate cancer), prostate cancer (adenocarcinoma)